Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR.

Diabetologia. 2012 Jun;55(6):1577-96. doi: 10.1007/s00125-012-2534-0. Epub 2012 Apr 20. No abstract available. Erratum in: Diabetologia. 2013 Mar;56(3):680.

PMID:
22526604
2.

The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.

Shang Q, Liu MK, Saumoy M, Holst JJ, Salen G, Xu G.

Am J Physiol Gastrointest Liver Physiol. 2012 Apr 15;302(8):G815-23. doi: 10.1152/ajpgi.00295.2011. Epub 2012 Jan 26.

PMID:
22281473
3.

Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.

Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, Fulcher G, de Galan BE, Harrap S, Hamet P, Heller S, MacMahon S, Marre M, Poulter N, Travert F, Patel A, Neal B, Woodward M; ADVANCE Collaborative Group.

Diabetologia. 2012 Mar;55(3):636-43. doi: 10.1007/s00125-011-2404-1. Epub 2011 Dec 21.

PMID:
22186981
4.

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

Knop FK, Aaboe K, Vilsbøll T, Vølund A, Holst JJ, Krarup T, Madsbad S.

Diabetes Obes Metab. 2012 Jun;14(6):500-10. doi: 10.1111/j.1463-1326.2011.01549.x. Epub 2012 Jan 17.

PMID:
22171657
5.

Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.

Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, Turner SM, Protasio J, Riiff T, Hellerstein MK.

Diabetologia. 2012 Feb;55(2):432-42. doi: 10.1007/s00125-011-2382-3. Epub 2011 Dec 2.

PMID:
22134839
6.

The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial.

Duckworth WC, Abraira C, Moritz TE, Davis SN, Emanuele N, Goldman S, Hayward R, Huang GD, Marks JB, Reaven PD, Reda DJ, Warren SR, Zieve FJ; Investigators of the VADT.

J Diabetes Complications. 2011 Nov-Dec;25(6):355-61. doi: 10.1016/j.jdiacomp.2011.10.003. Epub 2011 Nov 4.

PMID:
22055259
7.

Role of bile acid sequestrants in the treatment of type 2 diabetes.

Handelsman Y.

Diabetes Care. 2011 May;34 Suppl 2:S244-50. doi: 10.2337/dc11-s237. Review. No abstract available.

8.

Long-term effects of intensive glucose lowering on cardiovascular outcomes.

ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT.

N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524.

9.

Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism.

Brufau G, Stellaard F, Prado K, Bloks VW, Jonkers E, Boverhof R, Kuipers F, Murphy EJ.

Hepatology. 2010 Oct;52(4):1455-64. doi: 10.1002/hep.23831.

PMID:
20725912
10.

Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats.

Chen L, McNulty J, Anderson D, Liu Y, Nystrom C, Bullard S, Collins J, Handlon AL, Klein R, Grimes A, Murray D, Brown R, Krull D, Benson B, Kleymenova E, Remlinger K, Young A, Yao X.

J Pharmacol Exp Ther. 2010 Jul;334(1):164-70. doi: 10.1124/jpet.110.166892. Epub 2010 Apr 22.

11.

Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1.

Shang Q, Saumoy M, Holst JJ, Salen G, Xu G.

Am J Physiol Gastrointest Liver Physiol. 2010 Mar;298(3):G419-24. doi: 10.1152/ajpgi.00362.2009. Epub 2009 Dec 31.

PMID:
20044510
12.

Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice.

Herrema H, Meissner M, van Dijk TH, Brufau G, Boverhof R, Oosterveer MH, Reijngoud DJ, Müller M, Stellaard F, Groen AK, Kuipers F.

Hepatology. 2010 Mar;51(3):806-16. doi: 10.1002/hep.23408.

PMID:
19998408
13.

The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.

Vilsbøll T, Holst JJ, Knop FK.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):453-62. doi: 10.1016/j.beem.2009.03.011. Review.

PMID:
19748063
14.

TGR5-mediated bile acid sensing controls glucose homeostasis.

Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K.

Cell Metab. 2009 Sep;10(3):167-77. doi: 10.1016/j.cmet.2009.08.001.

15.

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M.

Diabetologia. 2009 Nov;52(11):2288-98. doi: 10.1007/s00125-009-1470-0. Epub 2009 Aug 5. Erratum in: Diabetologia. 2009 Nov;52(1):2470. Control Group [added].

PMID:
19655124
16.

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group.

BMJ. 2009 Jul 21;339:b2535. doi: 10.1136/bmj.b2535. No abstract available.

17.

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.

Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N.

Lancet. 2009 May 23;373(9677):1765-72. doi: 10.1016/S0140-6736(09)60697-8.

PMID:
19465231
18.

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS.

Am J Med. 2009 May;122(5):443-53. doi: 10.1016/j.amjmed.2008.09.047.

PMID:
19375554
19.

Role of bile acids and bile acid receptors in metabolic regulation.

Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B.

Physiol Rev. 2009 Jan;89(1):147-91. doi: 10.1152/physrev.00010.2008. Review.

PMID:
19126757
20.

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.

Bays HE, Goldberg RB, Truitt KE, Jones MR.

Arch Intern Med. 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975.

PMID:
18852398

Supplemental Content

Support Center